Study of the effect of curcumin on rheumatism

Study of the effect of oral curcumin on disease development in patients with rheumatoid arthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170812035630N1

Enrollment

Registered

2018-01-21

Start date

2017-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis Rheumatoid. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: In the intervention group for 3 months, patients treated with curcumin (in the form of nanomissile) are given as 80 mg (80 mg capsules) per day. Intervention 2: In the control group, f

Treatment - Drugs

Placebo

In the intervention group for 3 months, patients treated with curcumin (in the form of nanomissile) are given as 80 mg (80 mg capsules) per day.

In the control group, for 3 months, patients received placebo treatment at a dose of 80 mg (as capsule 80 mg placebo) per day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed with RA according to eular criteria Personal satisfaction

Exclusion criteria

Exclusion criteria: Curcumin sensitivity Diabetes Pregnancy

Design outcomes

Primary

Measure	Time frame
Disease activity. Timepoint: Before taking curcumin and 3 months after taking curcumin. Method of measurement: Questionnaire DAS 28 ( Disease Activity Square 28).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Saraf

Mashhad University of Medical Sciences

Afshinsarraf@Hotmail.Com+98 51 3801 2753

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026